CGRP inhibitors
https://themeditary.com/dosage-information/ubrelvy-dosage-1115.html

Ubrelvy Dosage

Drug Detail:Ubrelvy (Ubrogepant [ ue-broe-je-pant ])

Generic Name: UBROGEPANT 50mg

Dosage Form: tablet

Drug Class: CGRP inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions FAQ

2.1 Recommended Dosage

The recommended dose of UBRELVY is 50 mg or 100 mg taken orally with or without food.

If needed, a second dose may be taken at least 2 hours after the initial dose. The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.

2.2 Dosage Modifications

Dosing modifications for concomitant use of specific drugs and for patients with hepatic or renal impairment are provided in Table 1.

Table 1: Dose Modifications for Drug Interactions and for Specific Populations
Dosage Modifications
 Initial Dose
 Second Dosea
(if needed)
Concomitant Drug [see Drug Interactions (7)]
Moderate CYP3A4 Inhibitors (7.1) 50 mg Avoid within 24 hours
Weak CYP3A4 Inhibitors (7.1) 50 mg 50 mg
Strong CYP3A4 Inducers (7.2) Avoid concomitant use
Weak & Moderate CYP3A4 Inducers (7.2) 100 mg 100 mg
BCRP and/or P-gp only Inhibitors (7.3) 50 mg 50 mg
Specific Populations [see Use in Specific Populations (8)]
Severe Hepatic Impairment (Child-Pugh Class C) (8.6) 50 mg 50 mg
Severe Renal Impairment (CLcr 15-29 mL/min) (8.7) 50 mg 50 mg
End-Stage Renal Disease (CLcr <15 mL/min) (8.7) Avoid use

a Second dose may be taken at least 2 hours after the initial dose

Share this Article
Latest News
Related Drugs